Government Approvals, Patent Strategy & Regulatory

🏛️ India Regulatory Framework

Medical Device Regulatory Compliance

Prana MSR Health operates within a comprehensive Indian regulatory framework spanning device safety, digital health infrastructure, telemedicine, and data privacy — ensuring every module is audit-ready.

India Medical Device Regulatory Framework — CDSCO, ABDM, MoHFW, DPDPA

⚕️

CDSCO SaMD Classification

Under the Medical Devices Rules 2017 (as amended), AI-powered CDSS modules are classified as Software as a Medical Device (SaMD).

📋 Class A — Low Risk (General Wellness)N/A

📋 Class B — Moderate Risk (ED Triage AI)Filing Required

📋 Class C — Moderate-High (Sepsis/Oncology)Clinical Validation

📋 Class D — High Risk (Not Applicable)Exempt

📋 MD-14 Import License for hardwarePhase 0

📹

Telemedicine & e-Prescription Rules

Full compliance with MoHFW Telemedicine Practice Guidelines 2020 and Indian Medical Council (Professional Conduct) Regulations.

📹 First Consult: Mandatory Live VideoEnforced

💊 Schedule X Drug Ban in e-Rx PadHard-Coded

💊 Narcotic Drug Restriction (NDPS Act)Hard-Coded

📝 Registered Medical Practitioner OnlyKMC Verified

📝 Patient Consent Before TeleconsultMandatory

🛡️

Data Privacy & Sovereignty

Built-in compliance with the Digital Personal Data Protection Act 2023 (DPDPA) and India's data localisation requirements.

🔒 DPDPA Section 4 — Lawful ProcessingCompliant

🔒 DPDPA Section 6 — Consent FrameworkAWS Mumbai

🔒 Data Localisation (ap-south-1)Enforced

🔒 Right to Data Erasure (Section 12)Built-in

🔒 Local LLM — Zero Data EgressOllama

🔗 API Integration Hub

Government & Healthcare API Integrations

Prana MSR Health platform connects natively with India's Digital Public Infrastructure through certified APIs and sandbox-approved integrations.

Government API & Digital Health Integration Hub

🆔 Health Identity & Records Layer

🔗 ABHA ID Generation SDK (14-digit Health ID)Phase 1

🔗 ABDM Health Facility Registry (HFR)Registered

🔗 ABDM Health Professional Registry (HPR)Integrated

🔗 FHIR R4 Health Record ExchangeStandard

🔗 HIE-CM Consent Manager (Health Info Exchange)Mandatory

🔗 EHR Standards (ABDM M1/M2/M3)Compliant

🏥 Government Scheme & Verification APIs

🔗 KMC Doctor Verification API (Karnataka)Live

🔗 NMC (National Medical Commission) RegistryPhase 2

🔗 PMJAY Claims Submission APIPhase 2

🔗 Arogya Karnataka State Insurance APIPhase 2

🔗 NHA Sandbox Testing EnvironmentCertified

🔗 DigiLocker Integration (Patient Documents)Phase 3

🏗️

ISO 13485:2016

Medical Device QMS

OEM Compliant

🔐

ISO 27001

Information Security

Phase 2

🏥

IEC 62304

Medical Software Lifecycle

Planned

⚡

IEC 62366

Usability Engineering

Planned

🤝 Strategic Partnership

MSR Group × Lattice Consulting Joint Venture Patent Program

All technology patents for the MedAI platform are filed jointly by M.S. Ramaiah Group and Lattice Consulting Worldwide (OPC) Pvt Ltd — combining clinical authority with technology innovation.

M.S. Ramaiah Group

Hospital Network & Academic Institution

MSR Group serves as the clinical validation partner, providing hospital infrastructure, patient datasets, ethics board access, and academic credibility through M.S. Ramaiah Medical College.

🏥 Clinical Trial Site (MSR Hospital Network)Primary

📚 Academic Publications & Peer ReviewLead Author

⚖️ Institutional Ethics Committee (IEC) AccessApprover

🩺 Clinical Subject Matter ExpertsAdvisory

📊 Real-World Evidence Data (RWE)Provider

🏫 NAAC-Accredited Research CredentialsInstitutional

LC

Lattice Consulting Worldwide (OPC) Pvt Ltd

Technology & Software Engineering

Lattice Consulting serves as the technology IP owner, responsible for all AI architecture, system design, software engineering, and patent claim drafting for the MedAI platform.

🏗️ 7-Microservice System ArchitectureIP Owner

🤖 AI/ML Model Development (6 Clusters)Developer

💻 Source Code Copyright (All Modules)Registrant

📝 Patent Claim Drafting & FilingLead

🔒 Trade Secret Protection (Model Weights)Custodian

⚙️ HospitalEventEngine Simulation IPInventor

📋 Joint Patent Filing Structure

🏥

Clinical Trials & Validation

MSR Hospital Network conducts clinical validation studies, publishes peer-reviewed academic papers, and provides real-world evidence for patent claims. All publications bear MSR Group as lead institution.

LED BY: MSR GROUP

📜

Joint Technology Patents

All technology patents — system architecture, AI modules, simulation engine, LLM routing — are filed jointly by MSR Group and Lattice Consulting as co-applicants under Indian Patents Act.

JOINT: MSR + LATTICE

💻

Technology IP & Copyright

Source code copyright, model weights (trade secret), training pipelines, and system design documentation are owned by Lattice Consulting with perpetual license to MSR Group for clinical deployment.

LED BY: LATTICE CONSULTING

Phase 1 — Clinical

📊 Retrospective Study

MIMIC-IV retrospective validation published through MSR Medical College. Establishes baseline performance metrics for patent efficacy claims.

MSR Lead

Phase 2 — Prospective

🏥 Prospective Clinical Trial

Multi-site prospective validation across MSR Hospital network (5 rural Karnataka sites). IEC-approved protocol with real patient cohorts.

Joint MSR + Lattice

Phase 3 — Publication

📚 Peer-Reviewed Publication

Academic publication in indexed medical journals (BMJ Digital Health, JMIR) with MSR Group as institutional lead and Lattice as technology partner.

MSR Lead Author

📋 LCW-IP-2026-001 — Confidential

MedAI Patent Landscape Report

A comprehensive prior art search, freedom-to-operate analysis, and patentability assessment for the MedAI Platform — filed jointly by MSR Group × Lattice Consulting covering 6 technology clusters across India, USA, Europe, China, and PCT jurisdictions.

🔑

KEY FINDING

While individual technology components of MedAI (XGBoost triage, BiLSTM sepsis detection, etc.) have extensive prior art, the platform's UNIQUE VALUE lies in its integrated architecture: seven microservices operating as a single clinical continuum, powered by a real-time hospital simulation engine (HospitalEventEngine), a privacy-first local LLM layer, and MADDPG-based multi-agent hospital operations — all trained on MIMIC-IV and India-contextualised for CDSCO SaMD compliance. This integration is the patentable novel contribution.

⚙️ 6 Technology Clusters

Patentable Technology Portfolio

Each cluster represents a distinct, patent-eligible innovation within the MedAI platform.

Cluster 1 — Medical AI / CDS

🚑 AI-Powered ED Triage System

TriageXGBoost + TriageNN with a 59-feature pipeline trained on MIMIC-IV. Includes missingness-aware feature engineering, arrival-mode one-hot encoding, and confidence-weighted disposition routing.

India: 65–75%USA: 55–65%EPO: 60–70%

Cluster 2 — ICU Monitoring

🩸 Sepsis BiLSTM + Temporal Attention

Bidirectional LSTM with temporal attention over 6-hour sliding clinical windows. 19-variable × 6-aggregation (114 features) coupled with SOFA score integration and heuristic fallback.

EPO: 60–70% (strongest)India: 65–75%

Cluster 3 — Oncology AI

🔬 Multi-Task Oncology TabTransformer

Dual-task: 30-day readmission + in-hospital mortality using shared 16-feature MIMIC-IV vector. Combined risk score (0.6×readmission + 0.4×mortality) with NCCN-aligned treatment pathway generation.

EPO: 65–75%India: 65–75%USA: 55–65%

Cluster 4 — Healthcare Ops

🏥 MADDPG Multi-Agent Hospital Ops

8-department RL agents with centralised critic network, curriculum learning (ED → ED+ICU+Medicine → All 8 departments), Ornstein-Uhlenbeck noise, powered by HospitalEventEngine replaying MIMIC patient journeys.

India: 60–70%USA: 60–70% ⭐ Highest Novelty

Cluster 5 — Privacy Tech

🔒 Local LLM Clinical Chat (Zero-Egress)

Ollama-hosted local LLM with zero data egress. Per-session memory, smart query intent routing to ED Triage / Oncology / Patient Journey APIs, ABDM-linked patient identity integration.

USA: 65–75% ⭐ StrongestEPO: 65–75%

Cluster 6 — STRONGEST CLAIM

🏗️ Integrated Full-Stack CDSS Architecture

7-microservice monorepo, unified dashboard, ABDM integration, CDSCO SaMD Class B/C. System-level patents are hardest to design around and provide the broadest commercial protection.

India: 65–75%USA: 70–80%EPO: 65–75%

📊 Jurisdiction Analysis

Global Patent Grant Probability

Structured assessment across India (IPO/CRI 2025), USA (USPTO/Alice-Mayo), Europe (EPO), China (CNIPA), and PCT filing routes.

Patent Grant Probability Analysis across 5 jurisdictions

🇮🇳 India — IPO (CRI 2025)

The CRI Guidelines 2025 (effective July 29, 2025) fundamentally changed how AI/ML inventions are examined. Technical effect must be demonstrated — MedAI satisfies this with quantifiable clinical outcomes (mis-triage reduction, sepsis detection time, readmission rates).

Grant Probability: 65–75% — Strongest for system integration + HospitalEventEngine simulation

🇺🇸 USA — USPTO (Alice/Mayo)

Must overcome Alice/Mayo two-step: claims cannot be directed to abstract ideas. Strategy: follow McRO/Enfish/Bascom line — frame claims around specific technical improvements including NVIDIA GPU, MongoDB, Ollama inference hardware elements.

Grant Probability: 55–65% — System claims strongest (70–80%)

🇪🇺 Europe — EPO

Uses 'technical character' and 'technical contribution' framework — the most rigorous but also most predictable. EPO has granted numerous AI medical device patents where technical problem and solution are well-defined.

Grant Probability: 60–70% — Oncology module strongest (65–75%)

🇨🇳 China — CNIPA + PCT Global

CNIPA has relatively strong AI patent grant rates. PCT filing through Indian Patent Office allows global protection via single application, with national phase entry in 150+ countries after 30 months.

China: 60–70% | PCT: 50–65% — File early for ASEAN/Middle East gateway

📜 Novel Patent Claims

Recommended Patentable Claims

Specific novel elements identified as non-obvious and industrially applicable.

🏆 Primary Patent Application (System Architecture) — Joint Filing: MSR Group × Lattice Consulting

"An Integrated Clinical Decision Support System Comprising Heterogeneous AI Modules, Real-Time Hospital Simulation, and Privacy-Preserving Local LLM Interface for Healthcare Facilities"
Co-Applicants: M.S. Ramaiah Group (Clinical Validation & Academic Publications) + Lattice Consulting Worldwide (Technology IP & System Architecture)

1Independent (System): A clinical AI platform comprising seven microservices over shared MongoDB, real-time hospital simulation engine replaying patient journeys from historical EHR data, and local LLM inference layer with zero-data-egress. — No prior art combines all three elements

2Dependent (Simulation): Simulation engine dynamically generates synthetic admissions, transfers, chartevents, and prescriptions based on historical patient arrival heuristics — enabling live testing without production data risk. — Novel simulation-as-testing-environment

3Dependent (MADDPG Ops): Multi-agent RL module where each hospital department is an autonomous agent optimising continuous staffing actions under centralised critic, trained via curriculum learning. — No prior art teaches this specific architecture

4Dependent (LLM Routing): Local language model with query intent classification layer routing clinical queries to domain-specific API endpoints without transmitting patient data externally. — Novel intent routing + zero-egress

5Dependent (Data Architecture): Shared data layer comprising three logically separate databases for core clinical, ICU physiological, and narrative text data, accessed through thread-safe connection manager with lazy initialisation. — Novel 3-DB partition design

Module Patent 1

ED Triage — Missingness-Aware Feature Engineering

Method comprising binary missingness indicator features for vital signs/labs, one-hot patient arrival mode encoding, gradient-boosted 5-level acuity classification with confidence scoring and disposition routing.

Strongest: India (CRI 2025), EPO, USPTO

Module Patent 2

Sepsis — BiLSTM + Temporal Attention + SOFA

Computer-implemented method: 6-hour ICU windows, 6 statistical aggregations per variable producing 114 features, bidirectional LSTM with temporal attention, SOFA score overlay for clinical escalation.

Strongest: EPO, India, USPTO

Module Patent 3

Oncology — Dual Prediction + Treatment Pathway

Transformer encoder with learned positional embeddings, two independent prediction heads (readmission + mortality), combined risk score, and personalised oncology care pathway generator.

Strongest: EPO, India, USA, China

Module Patent 4

MADDPG — Hospital Staffing with Curriculum Learning

Plurality of RL agents per department, centralised critic with concatenated observations, curriculum learning protocol, reward function combining wait time minimisation + overcrowding penalty + throughput.

Strongest: India, EPO, USA — Strong FTO, no existing patent

🛡️ Freedom-to-Operate

Global Competitor IP Landscape

Understanding competitor patent portfolios is essential for freedom-to-operate analysis and positioning MedAI's claims.

Company	Country	Patent Volume	Closest Technology	IP Risk
Google (DeepMind)	USA	500+ AI/healthcare	EHR prediction, sepsis, NLP	HIGH
Epic Systems (Cosmos/CoMET)	USA	Growing (Cosmos AI)	Foundation models on 300M records	HIGH
IBM Watson (Merative)	USA	300+ CDS patents	Clinical decision support, oncology	MEDIUM-HIGH
Philips Healthcare	Netherlands	High (clinical monitoring)	ICU monitoring, sepsis scoring	MEDIUM-HIGH
Microsoft (Nuance)	USA	200+ healthcare AI	Clinical NLP, EHR integration	MEDIUM
AWS (HealthLake)	USA	Medium (no patent on TabTransformer)	TabTransformer — public domain	LOW
Qure.ai / Indian companies	India	Low-medium	AI radiology (different domain)	LOW

India Medical AI Patent Opportunity — No Direct Competitor

The integrated clinical AI CDSS space targeting ED triage + ICU + Oncology + Hospital Operations in a single Indian-market platform has NO direct Indian patent competitor. This is a significant first-mover filing opportunity for the MSR Group × Lattice Consulting joint venture.

⏰ Time-Critical

IP Protection Strategy Roadmap

Phase-wise filing strategy for MSR Group × Lattice Consulting to secure joint global patent rights for MedAI technology.

🚨

CRITICAL DEADLINE

Under the Indian Patents Act, if MedAI technology has been disclosed (including pitch decks, investor documents, or presentations), the MSR Group × Lattice Consulting joint venture has a 12-month window from the first disclosure date to file a patent application. Both co-applicants must file a provisional application IMMEDIATELY to preserve the priority date.

PHASE 1 — IMMEDIATE (0–30 DAYS)

📝 File Indian Provisional Patent (Cluster 6) — MSR + Lattice as co-applicantsCRITICAL

📝 Joint Inventor Declaration (MSR + Lattice)14 days

📝 FTO Opinion — Google/Epic portfolios30 days

📝 Document all prior disclosure dates14 days

📝 Trade secret protection (model weights)Immediate

PHASE 2 — SHORT-TERM (30–90 DAYS)

📝 Full Indian Patent (non-provisional)Filing

📝 PCT (India, USA, EPO, China, Japan, SG)Filing

📝 Sepsis BiLSTM + MADDPG Module PatentsProvisional

📝 Copyright — 7 microservices source codeRegistration

📝 NDA — MSR Group & tech partnersExecute

PHASE 3 — LONG-TERM (6–24 MONTHS)

📝 National phase: India, USA, EPO minimumPlanned

📝 Continuation patents (new modules)Ongoing

📝 Defensive publications (open-source)Strategy

📝 Competitor monitoring (Google, Epic)Ongoing

📝 TM: 'MedAI', 'Health Lattice'Register

Hybrid IP Protection Matrix — Patent, Trade Secret, Copyright

⚠️ Risk Assessment

IP Risk Assessment & Mitigation

RiskLikelihoodMitigation

Google/DeepMind EHR sepsis/triage patents blocking commercialisationMEDIUMDesign around via India-specific MIMIC-IV + CDSCO + local LLM layer

Epic CoMET foundation model patents blocking MIMIC-IV trainingLOW-MEDIUMCoMET is published research (Dec 2025) — emphasise simulation engine + MADDPG

Section 3(k) IPO rejection of algorithmic claims in IndiaHIGHDraft system claims with measurable clinical effects; follow CRI 2025

Alice rejection of AI medical claims at USPTOMEDIUM-HIGHMcRO/Enfish strategy; include hardware elements (NVIDIA, MongoDB, Ollama)

Prior disclosure triggering 12-month bar under Indian patent lawHIGHFile provisional immediately; document all disclosure dates

Chinese competitors (e.g., BGI) filing aggressive AI CDSS patentsMEDIUMFile PCT with China designated early; CNIPA supports technical systems

🏆 Summary

Patent Portfolio Scorecard

Filing EntityMSR Group × Lattice Consulting (Joint)

Overall Patent NoveltyHIGH — Integrated architecture novel

Prior Art DensityMEDIUM-HIGH — Combined application novel

Best First Filing JurisdictionIndia (lowest cost, CRI 2025 supports AI)

Recommended RouteIndian Provisional (Joint) → PCT → National Phase

Strongest ClaimsMADDPG + LLM routing + Simulation

Clinical ValidationMSR Hospital Network (Lead) + Academic Pubs

Time SensitivityCRITICAL — 12-month disclosure deadline

Estimated Patents Grantable2–4 patents over 3–5 year timeline

Commercial ValueHIGH — Blocks competitors, enables licensing

Estimated IP Budget₹40–60 lakh (USD 48K–72K) over 3–5 years

Timeline

Phase-Wise Approval & Procurement

Step-by-step strategy to transition from validation to mass government procurement.

Phase 0 — Foundation (Months 1-3)

Legal & Sandbox Clearances

Before physical deployment, laying the regulatory groundwork.

AWS Cloud Account & Security Audit: Setup in ap-south-1 (Mumbai) to ensure DPDPA 2023 data sovereignty compliance.
ABDM Sandbox Certification: Registering the MSR Connect platform on the National Health Authority (NHA) sandbox.
CDSCO MD-14 Filing: Initiating import licenses for hardware under Indian medical device rules.
KMC API Integration: Connecting to Karnataka Medical Council to verify RMP credentials natively during doctor onboarding.

Phase 1 — Market Entry (Months 4-7)

Validation & Pilot Implementations

Private deployments within the MSR Hospital network and 5 target rural districts (Ramanagara, Kolar, Tumkur, Mandya, Chikkaballapur).

Telemedicine Guidelines Enforced: System mandates synchronous live video for all first-time patient consults as per MoHFW 2020 rules.
e-Prescription Restrictions: Platform hard-codes Schedule X and Narcotic drug bans into the doctor's digital prescription pad.
Local Assembly Setup: Small-scale assembly of import CKD kits (Complete Knock-Down) in Bengaluru to optimize logistics.

Phase 2 — Scale-Up (Months 8-14)

KIADB Land Allotment & B2G Procurement

Shifting focus to localized manufacturing and government scheme integrations.

KIADB Manufacturing Facility: Applying for KIADB industrial land for localized component assembly.
PMJAY / Arogya Karnataka Integration: Syncing the platform with state nodal agencies to allow billing under government insurance schemes (unlocking 2.4 crore beneficiaries).
B2G Procurement (NHM & ZP): Bidding for district-level Zilla Panchayat tenders and National Health Mission funds for equipping PHCs.

Phase 3 — Full Make in India (Months 15+)

PLI Scheme & Nationwide Tenders

Transitioning to a highly localized, export-ready manufacturing base.

PLI Scheme Qualification: Achieving 80-85% domestic content to qualify for the Production Linked Incentive scheme (5% financial incentive).
Pan-India Expansion: Partnering with state governments outside Karnataka using successful pilot data as proof of concept.
Data & Research Governance: IRB approvals for anonymized population health data sharing with pharmaceutical partners.

Government Approvals, Patent Strategy & Public Health Integration

Clinical & Hardware Regulatory (CDSCO)

Digital Public Infrastructure (ABDM)